ARIAD Pharma (ARIA) Ticks Higher Following Preliminary Ponatinib Phase 2 Data
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Join SI Premium – FREE
ARIAD Pharmaceuticals (Nasdaq: ARIA) is trading higher early Monday morning, following preliminary data showing pan-BCR-ABL inhibitor, ponatinib, showing that 47 percent of chronic-phase CML patients in the trial achieved a major cytogenetic response to date, including 65 percent of patients who have a T315I mutation. Data were presented following a Phase 2 study. Click here for more.
Shares are up 3 percent ahead of the bell.
Shares are up 3 percent ahead of the bell.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial
- Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
- NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
